Coya Therapeutics’ COYA 302 ALS trial accepted by NEALS research consortium

Coya Therapeutics (COYA)’ upcoming Phase 2 clinical trial to evaluate the efficacy and safety of COYA 302 in patients with ALS has been accepted as a NEALS-Affiliated Trial by the NEALS Consortium. The NEALS Consortium is the world’s largest ALS research network, comprising a highly active group of trial-ready sites with deep expertise in designing and managing FDA-regulated clinical studies. For more than 30 years, NEALS has partnered with both industry and academic investigators to conduct ALS trials, guided by a leadership team committed to accelerating treatment development for people living with ALS. As a NEALS-affiliated study, the COYA 302 Phase 2 clinical trial will benefit from support across NEALS’ institutional and community networks. The study will be presented on September 29 during the NEALS Educational Webinar.